Concord Biotech Limited

BSE: CONCORDBIO543960ISIN INE338H01029

Healthcare
Pharmaceuticals
BSE 500

BSE listing

Share price

₹1,493.90+31.80 (+2.17%)

as of 18 Sep 2026

52W high: ₹1,702.10
52W low: ₹987.05
Off 52W high: -12.23%
1M return: -5.75%
3M return: +13.47%
6M return: +36.75%
1Y return: -9.78%
20D avg volume: 1,17,900
50 DMA: ₹1,421.70
200 DMA: ₹1,269.17

Key ratios Consolidated

Market cap: ₹15,629 Cr
Current price: ₹1,493.90
52W high / low: ₹1,702.10 / ₹987.05
Face value: ₹1.00
P/E: 57.28
P/B: —
EPS (TTM): ₹26.08
Book value / share: —
ROE: —
ROCE: 16.60%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹-12.19 Cr
Interest cover: 1,221.50
Dividend yield: 0.51%
Dividend / share (TTM): ₹7.55
Payout: 28.95%
Cash conversion cycle: 236.8 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	257.49	326.08	277.77	247.06	203.99	429.88	244.22	310.18	215.80	318.97	240.80	262.35
	12.83	15.35	9.98	13.35	13.68	9.38	14.73	10.03	10.31	10.81	8.19	8.13
	193.25	227.18	197.61	177.02	160.43	254.17	159.63	186.91	147.94	198.86	148.90	157.29
	69.85	70.54	66.59	57.30	59.91	80.27	60.96	68.05	55.03	55.67	47.39	42.00
	11.29	15.67	20.45	13.65	12.85	10.32	12.19	21.70	11.78	11.45	23.22	10.47
	43.64	47.77	46.78	44.46	37.90	38.97	34.64	33.66	31.66	33.95	30.67	30.17
	0.04	0.08	0.08	0.06	0.06	0.10	0.10	0.10	0.24	0.46	0.49	0.84
	18.10	19.54	18.75	18.39	17.78	14.62	13.26	13.31	13.18	13.72	13.54	13.29
	77.18	73.96	66.27	65.09	59.59	72.00	—	63.52	54.56	61.88	57.11	60.12
	77.07	114.25	90.13	83.39	57.24	185.09	99.32	133.29	78.17	130.92	100.08	113.18
	0.00	0.00	-3.28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	77.07	114.25	86.85	83.39	57.24	185.09	99.32	133.29	78.17	130.92	100.08	113.18
	20.65	25.61	22.51	22.62	14.67	43.16	25.23	34.59	19.93	33.70	25.53	28.68
	57.70	88.47	63.64	63.06	44.06	140.39	75.92	95.74	59.59	95.02	77.57	81.02
	5.52	8.46	6.08	6.03	4.21	13.42	7.26	9.15	5.70	9.08	7.41	7.74
Key metrics
	95.21	133.87	105.68	101.84	75.08	199.81	112.68	146.70	91.59	145.10	114.11	127.31
	37.00%	41.10%	38.00%	41.20%	36.80%	46.50%	46.10%	47.30%	42.40%	45.50%	47.40%	48.50%
	22.40%	27.10%	22.90%	25.50%	21.60%	32.70%	31.10%	30.90%	27.60%	29.80%	32.20%	30.90%
	—	5.50%	—	4.50%	—	10.00%	—	—	—	—	—	—
	26.20%	-24.10%	13.70%	-20.30%	-5.50%	34.80%	1.40%	18.20%	—	—	—	—
	31.00%	-37.00%	-16.20%	-34.10%	-26.10%	47.70%	-2.10%	18.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	1,108	1,055	1,200	1,017
	51.51	52.36	44.45	33.78
	795.06	762.23	748.66	641.53
	264.28	254.35	264.31	184.54
	61.06	62.61	55.99	56.74
	182.65	176.90	138.93	123.05
	0.26	0.28	0.53	2.55
	74.78	74.46	54.37	53.59
	282.50	264.91	249.31	233.14
	364.84	345.01	495.88	409.19
	-3.28	-3.28	0.00	0.00
	361.56	341.74	495.88	409.19
	91.39	85.42	122.91	104.46
	272.87	259.23	371.64	308.10
	26.09	24.78	35.52	29.45
Key metrics
	436.60	416.48	550.78	465.33
	39.39%	39.50%	45.90%	45.80%
	24.62%	24.60%	31.00%	30.30%
	—	16.60%	26.80%	—
	—	-12.10%	18.00%	—
	—	-30.20%	20.60%	—
	—	171.73	133.35	—
	—	1.03	0.66	—
	—	0.00	0.00	—
	—	-12.19	-0.52	—
	—	236.8	197.2	—
Balance sheet
	—	2,235	2,034	—
	—	1,250	1,135	—
	—	12.19	0.90	—
	—	460.20	521.65	—
	—	326.36	239.67	—
	—	22.68	—	—
	—	785.72	791.80	—
	—	101.91	113.04	—
	—	169.08	184.06	—
	—	0.00	0.38	—
	—	0.00	0.38	—
	—	0.00	0.00	—
	—	2,015	1,813	—
Cash flow
	—	266.88	244.52	—
	—	-142.72	-159.99	—
	—	-112.88	-98.77	—
	—	95.15	111.17	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	260.52	325.89	278.13	247.06	203.99	429.88	244.22	310.18	215.80	318.97	240.80	262.35
	13.10	15.54	10.08	13.43	13.68	9.38	14.73	10.03	10.31	10.81	8.19	8.13
	191.40	223.06	194.64	174.97	160.43	254.17	159.63	186.91	147.94	198.86	148.90	157.29
	69.85	70.54	66.59	57.30	59.91	80.27	60.96	68.05	55.03	55.67	47.39	42.00
	11.26	15.67	20.07	13.65	12.85	10.32	12.19	21.70	11.78	11.45	23.22	10.48
	41.18	45.02	44.09	43.18	37.90	38.97	34.64	33.66	31.66	33.96	30.67	30.17
	0.01	0.06	0.06	0.06	0.06	0.10	0.10	0.10	0.24	0.46	0.50	0.84
	18.05	19.49	18.67	18.39	17.78	14.62	13.26	13.31	13.18	13.72	13.54	13.30
	76.52	72.82	65.66	64.32	59.59	72.00	—	63.52	54.56	61.88	57.11	60.12
	82.21	118.38	93.57	85.52	57.24	185.09	99.32	133.29	78.17	130.92	100.08	113.18
	0.00	0.00	-3.28	0.00	0.00	0.00	—	—	—	—	—	—
	82.21	118.38	90.30	85.52	57.24	185.09	99.32	133.29	78.17	130.92	100.08	113.18
	21.02	28.36	22.51	22.62	14.67	43.16	25.23	34.59	19.93	33.70	25.53	28.68
	61.19	90.02	67.78	62.90	42.57	141.94	74.09	98.70	58.24	97.21	74.55	84.49
	5.85	8.60	6.48	6.01	4.07	13.57	7.08	9.43	5.57	9.29	7.13	8.08
Key metrics
	100.27	137.93	109.03	103.97	75.08	199.81	112.68	146.70	91.59	145.10	114.12	127.32
	38.50%	42.30%	39.20%	42.10%	36.80%	46.50%	46.10%	47.30%	42.40%	45.50%	47.40%	48.50%
	23.50%	27.60%	24.40%	25.50%	20.90%	33.00%	30.30%	31.80%	27.00%	30.50%	31.00%	32.20%
	—	5.70%	—	4.60%	—	10.00%	—	—	—	—	—	—
	27.70%	-24.20%	13.90%	-20.30%	-5.50%	34.80%	1.40%	18.20%	—	—	—	—
	43.70%	-36.60%	-8.50%	-36.30%	-26.90%	46.00%	-0.60%	16.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	1,112	1,055	1,200	1,017
	52.15	52.73	44.45	33.78
	784.07	753.09	748.66	641.53
	264.28	254.35	264.31	184.54
	60.65	62.23	55.99	56.74
	173.47	170.19	138.93	123.05
	0.19	0.23	0.53	2.55
	74.60	74.33	54.37	53.59
	279.32	262.39	249.31	233.14
	379.68	354.71	495.88	409.19
	-3.28	-3.28	0.00	—
	376.41	351.43	495.88	409.19
	94.51	88.17	122.91	104.46
	281.89	263.27	372.96	304.73
	26.94	25.17	35.65	29.13
Key metrics
	451.20	425.99	550.78	465.33
	40.59%	40.40%	45.90%	45.80%
	25.36%	25.00%	31.10%	30.00%
	—	17.00%	26.80%	—
	—	-12.10%	18.00%	—
	—	-29.40%	22.40%	—
	—	168.74	133.35	—
	—	1.00	0.66	—
	—	0.00	0.00	—
	—	-7.89	-0.52	—
	—	237.0	197.2	—
Balance sheet
	—	2,237	2,034	—
	—	1,245	1,135	—
	—	7.89	0.90	—
	—	460.60	521.65	—
	—	325.69	239.67	—
	—	22.28	—	—
	—	785.63	791.80	—
	—	101.18	113.04	—
	—	167.24	184.06	—
	—	0.00	0.38	—
	—	0.00	0.38	—
	—	0.00	0.00	—
	—	2,020	1,813	—
Cash flow
	—	263.78	244.52	—
	—	-142.28	-159.99	—
	—	-114.51	-98.77	—
	—	95.04	111.17	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): -6.45%
Profit YoY (TTM): -21.11%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): -6.72%
Profit YoY (TTM): -23.37%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 44.08%

Holder	Type	Holding	Previous	Change
Sudhir Kumar Vaid	Promoter	28.84%	—	—
Manju Vaid	Promoter Group	9.55%	—	—
Nishtha JhunjhunwalaDiscretionary Trust	Public	8.03%	—	—
Aryavir Jhunjhunwala Discretionary Trust	Public	8.03%	—	—
Aryaman Jhunjhunwala Discretionary Trust	Public	8.03%	—	—
Sudman Consultants Llp	Promoter Group	4.54%	—	—
Government Pension Fund Global	Public	2.95%	—	—
Tata Aia Life Insurance Co Ltd Unit Linked Multi Cap Fund	Public	2.48%	—	—
1575773 Ontario Inc	Public	2.00%	—	—
Dsp Small Cap Fund	Public	1.75%	—	—
Axis Max Life Insurance Limited A/C Reversionary Bonus Participating - Equity	Public	1.34%	—	—
Ravindra Raichand Dharamshi	Public	1.20%	—	—
Chanakya Corporate Services Pvt Ltd	Public	1.11%	—	—
Ohm Stock Broker Private Limited	Public	1.05%	—	—
Ankur Sudhir Vaid	Promoter	0.56%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/09/2026 ,inter alia, to consider and approve the proposal for declaration ....19 Sep 2026 · Board Meeting / Board Meeting
Intimation of Outcome of U.S. Food and Drug Administration (USFDA) Inspection at Unit II - Valthera Formulation Facility of the Company.18 Sep 2026 · Company Update / General
Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time ....17 Sep 2026 · Company Update / Analyst / Investor Meet
We would like to inform you that the officials of the Company will be attending an Investor Conference on 26th August 2026 as per the schedule and details in the file uploaded herewith.21 Aug 2026 · Company Update / Analyst / Investor Meet
Transcript of Q1 - FY27 Earnings call held on August 03, 20267 Aug 2026 · Company Update / Earnings Call Transcript
The audio recording of the conference held on August 03, 2026 has been hosted on the website of the company and link to access the said recording is as follows: - Link : https://concordbiotech.com/wp-content/uploads/2026/08/Concord-Biotech-Q1-FY27-Earnings-Call-Audio-Recording.mp3 ....3 Aug 2026 · Company Update / Analyst / Investor Meet
Investors'' Presentation on unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 20261 Aug 2026 · Company Update / Investor Presentation
Pursuant to regulation 44(3) of the SEBI (LODR) Regulations, 2015 and section 108 of the Companies Act, 2013, the voting results along with the scrutinizers report for the business items ....1 Aug 2026 · AGM/EGM / AGM
Newspaper publication cutouts of unaudited Standalone and Consolidated Financial results for the first quarter ended June 30, 20261 Aug 2026 · Company Update / Newspaper Publication
The 41st Annual General Meeting Meeting of the Members of the Company was held on Friday July, 31, 2026 at 12:00 Noon through VC/OAVM. The summary of the proceedings are published herewith.31 Jul 2026 · AGM/EGM / AGM
Unaudited Standalone and Consolidated Financial Results for the first quarter ended on June 30, 202631 Jul 2026 · Result / Financial Results
We would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, July 31, 2026, on review and recommendation of Audit Committee of the Company, ....31 Jul 2026 · Board Meeting / Outcome of Board Meeting
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended from time to time, read with Para A of Schedule III thereto, We wish to inform you that the Company has arranged ....28 Jul 2026 · Company Update / Analyst / Investor Meet
Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve the unaudited Standalone and ....28 Jul 2026 · Board Meeting / Board Meeting
Newspaper Advertisement for Notice of 41st Annual General Meeting, Book Closure and Remove e-voting information8 Jul 2026 · Company Update / Newspaper Publication
The register of members and share transfer book of the Company will be closed from Saturday, July 25, 2026 to Friday, July 31, 2026. Further the Company has fixed Friday, July 24, 2026 ....7 Jul 2026 · Corp. Action / Record Date
Business Responsibility and Sustainability Report for financial year 2025-267 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report for the financial year 2025-267 Jul 2026 · Others / Reg. 34 (1) Annual Report
The Notice of 41st Annual General Meeting of the Company of scheduled to be held on Friday, July 31, 2026 through Video Conferencing (VC) / Other Audio-visual means(OAVM) at 12:00 Noon ....7 Jul 2026 · AGM/EGM / AGM
Newspaper advertisement for Notice of 41st Annual General Meeting.6 Jul 2026 · Company Update / Newspaper Publication
In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we furnish herewith certificate dated July 01, 2026 issued by MUFG Intime India Private Limited ....6 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and as per the Company''s code of conduct for Regulating, Monitoring and Reporting ....27 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
We are pleased to announce the successful completion of inspection by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda at Unit - II formulation ....25 Jun 2026 · Company Update / General
We are pleased to announce that the Company has entered into an agreement to Invest in M/s. FSGE Renewable Power Private Limited for installation of Wind Solar Hybrid Power Project having ....20 Jun 2026 · Company Update / Acquisition
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, scheduled to be held on 24th & 25th June, 2026.19 Jun 2026 · Company Update / Analyst / Investor Meet
Intimation of Schedule of Analyst / Institutional Investor meeting to be held on June 17, 2026 at 10:30 AM13 Jun 2026 · Company Update / Analyst / Investor Meet
We are pleased to announce the successful completion of an ANVISA inspection conducted by the Brazilian Health Regulatory Agency at our API manufacturing facility in Limbasi. The inspection ....12 Jun 2026 · Company Update / General
We are pleased to inform that the Company has received approval from USFDA for its ANDA for Tofacitinib Tablets, 5 mg and 10 mg.10 Jun 2026 · Company Update / General
Transcript of Q4 & FY26 Earnings call held on June 01, 20265 Jun 2026 · Company Update / Earnings Call Transcript
We are pleased to inform that the Company has received approval from USFDA for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.2 Jun 2026 · Company Update / General
Earning Call Recording- For the Quarter and financial year ended on March 31, 20261 Jun 2026 · Company Update / Analyst / Investor Meet
Pursuant to Regulation 30 and Schedule III part A of SEBI Listing Regulations, Investor Presentation on audited Standalone and Consolidated Financial Results for the quarter and financial ....30 May 2026 · Company Update / Investor Presentation
Extracts of newspaper publications dated May 30, 2026 of the audited Standalone and Consolidated financial results for the quarter and year ended March 31, 2026.30 May 2026 · Company Update / Newspaper Publication
The Board has recommended dividend of Rs. 7.55 per equity share of face value of Rs. 1 each fully paid up for the Financial Year 2025-26.29 May 2026 · Corp. Action / Dividend
Appointment of Cost Auditors and Internal Auditors29 May 2026 · Company Update / Change in Management
The Board of Directors of the Company, at its meeting held today i.e. Friday, May 29, 2026 appointed Mrs. Ekta Gupta as Independent Director(Additional) of the company.29 May 2026 · Company Update / Change in Management
Audited Standalone and Consolidated Financial Results for the fourth quarter and financial year ended on March 31, 202629 May 2026 · Result / Financial Results
Outcome of Board Meeting held today i.e. Friday, May 29, 2026 wherein the Board inter-alia considered and approved Audited Financial results and statements for the Financial Year ended ....29 May 2026 · Board Meeting / Outcome of Board Meeting
Pursuant to the regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed Annual Secretarial Compliance Report for the financial year ended ....26 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
The Company has arranged Earnings Call with Investor/Analyst (Participants) to discuss the audited Standalone and Consolidated Financial Results of the Company for the quarter and financial ....26 May 2026 · Company Update / Analyst / Investor Meet

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 7.5500	24 Jul 2026	24 Jul 2026	—
Final Dividend - Rs. - 10.7000	3 Sep 2025	3 Sep 2025	—

Board meetings

31 Jul 2026 Board Meeting - Financial Results